Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/66473
metadata.dc.identifier.doi: https://doi.org/10.56042/ijbb.v62i10.20912
Title: Computational insights into Curcumin's modulation of Epithelial-mesenchymal transition in pulmonary fibrosis
Authors: Shivangi, Km
Muyal, Jai Prakash
Mishra, Amaresh
Keywords: In silico;Molecular docking;Preclinical validation;Protein-protein interaction;SwissADME;Toxicity prediction
Issue Date: Oct-2025
Publisher: NIScPR-CSIR, India
Abstract: Pulmonary fibrosis (PF) is a progressive interstitial lung disease characterized by excessive production and accumulation of extracellular matrix, resulting in permanent lung damage. The epithelial-mesenchymal transition (EMT) plays a central part in the development of fibrosis; however, therapeutic strategies targeting EMT remain limited. Curcumin, a natural polyphenol with known anti-inflammatory and anti-fibrotic properties, presents a promising candidate for modulating EMT. This study aimed to evaluate the potential of curcumin as an EMT-targeting agent in pulmonary fibrosis using computational approaches. Protein targets of curcumin were predicted using the SwissTargetPrediction and STITCH databases. Protein-protein interaction (PPI) networks were analysed via STRING. Molecular docking studies were performed using AutoDock Vina with EMT-related proteins (TGFBR1, EGFR, MAPK1, and MMP9). Drug-like and pharmacokinetic properties were assessed using SwissADME, while toxicity was evaluated through Protox-II. Curcumin demonstrated strong binding affinity for multiple EMT regulators, suggesting potential inhibitory activity. Network analysis revealed dense interconnectivity among curcumin targets, indicating a co-regulated EMT-related functional cluster. Curcumin also exhibited favourable drug-like parameters and a low predicted toxicity profile (LD50: 2000 mg/kg). This study supports the role of curcumin as a multitarget modulator of epithelial-mesenchymal transition (EMT) with therapeutic relevance in pulmonary fibrosis. The results warrant further experimental validation to confirm its efficacy and safety in preclinical models.
Page(s): 1111-1117
ISSN: 0975-0959 (Online);0301-1208 (Print)
Appears in Collections:IJBB Vol.62(10) [October 2025]

Files in This Item:
File Description SizeFormat 
IJBB 62(10) 1111-1117.pdf1.24 MBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.